ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$92.51
+1.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 114.0K | 83.0K | 27.0K | 111.0K | 114.0K |
| Gross Profit | (114.0K) | (83.0K) | (27.0K) | (111.0K) | (114.0K) |
| Operating Expenses | |||||
| R&D Expense | 129.0M | 100.6M | 75.1M | 1.0M | 4.5M |
| SG&A Expense | 25.9M | 21.3M | 13.0M | 6.2M | 5.3M |
| General & Admin Expense | 4.9M | — | — | — | — |
| Selling & Marketing Expense | 200.0K | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 155.0M | 122.0M | 88.1M | 7.2M | 9.7M |
| Cost and Expenses | 155.1M | 122.1M | 88.1M | 7.3M | 9.8M |
| Operating Income (EBIT) | (155.1M) | (122.1M) | (88.1M) | (7.3M) | (9.8M) |
| Non-Operating | |||||
| Interest Income | 22.2M | 16.6M | 5.9M | 2.0M | 675.0K |
| Interest Expense | — | — | 1.5M | — | — |
| Net Interest Income | 22.2M | 16.6M | 4.4M | 2.0M | 675.0K |
| Other Non-Op Income/Expense | 22.2M | 16.6M | 4.4M | 2.0M | (85.0K) |
| Non-Operating Income (excl Interest) | (13.3M) | (16.6M) | (5.9M) | (2.0M) | 85.0K |
| EBT (Pre-Tax Income) | (132.9M) | (105.4M) | (83.7M) | (5.3M) | (9.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (132.9M) | (105.4M) | (83.7M) | (5.3M) | (9.9M) |
| Earnings from Cont. Ops | (132.9M) | (105.4M) | (83.7M) | (5.3M) | (9.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (132.9M) | (105.4M) | (83.7M) | (5.3M) | (9.9M) |
| Per Share | |||||
| Basic EPS | ($2.47) | ($2.31) | ($4.99) | ($4.44) | ($8.27) |
| Diluted EPS | ($2.47) | ($2.31) | ($4.99) | ($4.44) | ($8.27) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 62.9M | 45.6M | 16.8M | 14.4M | 14.4M |
| Diluted Shares Outstanding | 62.9M | 45.6M | 16.8M | 14.4M | 14.4M |
| Profitability Metrics | |||||
| EBITDA | (141.7M) | (105.3M) | (82.2M) | (5.2M) | (9.8M) |
| D&A | 134.0K | 83.0K | 27.0K | 111.0K | 114.0K |
| EBIT | (141.8M) | (105.4M) | (82.3M) | (5.3M) | (9.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026